|
Synonyms: compound 11 [US20190225610]
Compound class:
Synthetic organic
Comment: Adonertinib is the INN for an epidermal growth factor receptor inhibitor with antineoplastic potential. Released in the WHO INN Proposed List 135 (July 2026), the chemical structure is claimed in Nanjing Chuangte Pharmaceutical's patent US20190225610A1 [1]. The company pipeline lists FHND9041 as an irreversible, third-generation EGFR inhibitor that is designed to target EGFR in lung tumours with sensitive mutations such as T790M/L858R (double mutant). We can surmise that adonertinib may be the INN for FHND9041.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
Download 2D Structure ![]() |
|
| Canonical SMILES | Download |
| Isomeric SMILES | Download |
| InChI standard identifier | Download |
| InChI standard key | Download |
Molecular structure representations generated using Open Babel